UNSPSC 51142431: Methysergide maleate

This classification denotes a cns stimulant with the molecular formula C21H27N3O2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2U7H1466GH, chemically known as 9,10-didehydro-n-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8beta-carboxamide maleate (1:1) (salt) but more generally known as methysergide maleate, which bears US NIH Compound Identifier 5281073. European Medicines Agency schedules Methysergide maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03263MIG.

UNSPSC 51142431 Methysergide maleate is a Commodity code that nominally designates a specific pharmaceutical product, but recent state and local solicitations tagged under it show little activity directly aligned with that narrow scope. The three opportunities on record span pharmaceuticals more broadly — naloxone procurement for emergency response, therapeutic pharmacy initiatives exploring direct manufacturer relationships, and generic multi-source pharmaceuticals through cooperative purchasing. The issuing bodies include a county public health department (Seminole County, Florida), a state health and human services commission (Texas HHS Commission), and a multi-state cooperative purchasing alliance (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota and Oregon). The work being bought ranges from off-the-shelf naloxone and drug deactivation systems with fixed annual volumes to market research on direct-to-manufacturer prescription models and comprehensive generic pharmaceutical supply agreements serving multiple state and local facilities through authorized wholesalers.

Recent activity appears concentrated in Florida and the upper Midwest, with secondary visibility in Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023. The Texas HHS Commission issued RFI HHS0017013 in April 2026 as exploratory market research on direct-to-manufacturer prescription programs, seeking vendor capability information rather than formal bids. Minnesota's MMCAP issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The code shows limited recent relevant activity; the Seminole County and MMCAP opportunities align more closely with general pharmaceutical procurement than with methysergide maleate specifically, suggesting either broad tagging practices or misclassification at posting.